Arrhythmias caused by ondansetron: Case report

Juan M. Chala Tandrón1, MD; Liset Jiménez Fernández2, MD, MSc; Zoila Armada Esmores2, MD, MSc; Yudileyd Brito Ferrer2, MD, MSc; Melba Zayas González2, MD, MSc; and Maiyen García Arcia2, MD

1 Department of Anesthesiology and Resuscitation, Hospital Oncológico Universitario “Dr. Celestino Hernández Robau”. Santa Clara, Villa Clara, Cuba.
2 Department of Pharmacology, Universidad de Ciencias Médicas de Villa Clara. Santa Clara, Villa Clara, Cuba.

ABSTRACT

The ondansetron is used to prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery, belonging to the serotonin 5-HT3 receptor antagonists, a natural substance that can cause nausea and vomiting, and it blocks its action. The ondansetron is packaged in the form of rapid disintegration tablets, as a solution to be taken orally and in ampules, for parenteral use. The case of a 67-year-old female patient is presented, with a diagnosis of breast carcinoma, who underwent radical mastectomy with axillary dissection was performed, and who received chemotherapy with adriamycin, cyclophosphamide and paclitaxel; as well as ondansetron to treat nausea and vomiting. The patient presented a wide QRS complex tachycardia after taking the drug.

Keywords: Ondansetron, Cardiac arrhythmias, Wide QRS complex tachycardia

INTRODUCTION

Ondansetron is a serotonin 5-HT3 receptor antagonist widely used as an antiemetic agent after chemotherapy, radiotherapy and surgery. It affects the peripheral and central nerves reducing the activity of the vagus nerve, which deactivates the vomiting center in the spinal bulb; and blocks sero-
Arrhythmias caused by ondansetron

tonin receptors in the chemoreceptor trigger zone. The drug is available as 4 mg and 8 mg dissolving tablets and oral solution also in (4 mg and 8 mg ampules). The first dose of ondansetron is usually taken 30 minutes before the start of chemotherapy, 1 to 2 hours before the start of radiotherapy, or 1 hour before surgery. Additional doses are sometimes taken one to three times a day during chemotherapy or radiotherapy and for one to two days after the end of treatment.

Among the toxicities of Ondansetron there is a known risk of QTc prolongation on the ECG with the risk of cardiac arrhythmia which includes torsades de pointes without knowing the exact magnitude of such prolongation. Such effect on QTc has been evaluated in randomized, controlled, double-blind studies. It has been described in both the child and adult, and it can compromise the life of pediatric patients.

Patients with the highest risk of suffering torsades de pointes are those having pre-existing cardiac disorders such as congenital long QT syndrome, predisposition to hypokalemia or hypomagnesemia, or those taking medications that cause prolongation of the QT interval. That is why the cardiovascular effects produced by ondansetron need to be thoroughly assessed.

CASE REPORT

A 67-year-old woman with a history of atopy, arterial hypertension and intranodal re-entry tachycardia, for which she was treated with enalapril (20 mg/day), hydrochlorothiazide (25 mg/day) and verapamil (320 mg/day); who underwent radical mastectomy with axillary emptying and chemotherapy with 4 cycles of adriamycin and cyclophosphamide, and another 4 cycles of paclitaxel under the diagnosis of right breast adenocarcinoma.

At the beginning of chemotherapy, she was commenced on ondansetron 8 mg taken orally every 8 hours. From the second tablet the patient began to feel increases in heart rate of up to 150 beats per minute, and with the fourth tablet she began with asthenia, anorexia, dizziness and strong palpitations. Upon arrival at the emergency department, an electrocardiogram was performed where a regular tachycardia with wide QRS was observed (Figure 1), which resolved with electrical cardioversion. Figure 2 shows its basic rhythm.

The case was jointly discussed and the possibility...
of changing the chemotherapy regimen to try drugs that did not prolong the QT interval was assessed; but the patient showed a detailed treatment regimen and the appearance of arrhythmias where increased heart rate was associated with the ondansetron doses. Therefore, it was decided to maintain the same chemotherapy regimen and ondansetron administration was stopped; clinical or electrocardiographic manifestations completely ceased.

**COMMENTS**

Since there are few studies about the adverse cardiovascular effects of ondansetron and being widely used for nausea and vomiting from radiotherapy and chemotherapy, we must take into account some aspects.

**Recommendations for the use of ondansetron:**
- Ondansetron should be avoided in patients with congenital long QT syndrome, as well as in those at particular risk for cardiac arrhythmias or QT prolongation due to: administration of other drugs that prolong QT, congestive heart failure, hypokalemia, hypomagnesemia and bradycardrhythmias.
- For pediatric and adult patients receiving ondansetron as prophylaxis or treatment for postoperative nausea and vomiting, or for those caused by chemotherapy, no changes in dosage are suggested.
- In the prophylaxis of postoperative nausea and vomiting, as well as those caused by chemotherapy, single intravenous doses greater than 16 mg should be avoided.

These drugs should not be administered with ondansetron:
- Antiarrhythmics: amiodarone, dronedarone, disopyramide, flecainide, sotalol.
- Antimicrobials: macrolides and quinolones.
- Antifungals: fluconazole, ketoconazole.
- Antidiarrheals and antiemetics: domperidone, granisetron, loperamide, metoclopramide.
- Antimalarials: quinine, chloroquine.
- Antipsychotics: chlorpromazine, clozapine, droperidol, fluphenazine, haloperidol, olanzapine, pimozide, risperidone.
- Antidepressants: amitriptyline, citalopram, escitalopram, dosulepin, doxepine, fluoxetine, imipramine, loperamide.
- Miscellaneous: methadone, antiretrovirals (foscarinet), protein kinase inhibitors (sorafenib, suniti-

**Figure 2.** Baseline electrocardiogram of the patient, without ondansetron.
Arrhythmias caused by ondansetron

tinib), omeprazole, diphenhydramine, furosemide.

REFERENCES